New chemo combo targets cancer belly fluid in early trial

NCT ID NCT07397819

Recruiting now Disease control Sponsor: Dong sheng Zhang Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a chemotherapy drug called liposomal irinotecan, given directly into the belly, for people with malignant ascites (fluid buildup from cancer) who have not responded to standard treatments. The trial has two phases: first, finding the safest dose, then testing if it works alone or with other drugs. About 48 adults with digestive system cancers are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomal irinotecan (a chemotherapy drug in fat particles), given alone or with recombinant mutant human tumor necrosis factor or bevacizumab
What this could lead to: If successful, this could offer a new treatment option to control fluid buildup in the belly for people with advanced cancer who have run out of standard options.
What could go wrong: This is an early-phase trial with only 48 participants, so results may not apply to everyone. The drug may cause side effects or fail to control the fluid effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT ASCITES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT ASCITES

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510555, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.